论文部分内容阅读
[目的]研究核苷类药物治疗失代偿期乙型、丁型重叠感染肝炎肝硬化48周的临床疗效。[方法]24例失代偿期乙型、丁型重叠感染肝炎肝硬化患者在内科综合治疗基础上口服拉米夫定100 m g每日1次。疗程中监测患者生化学指标（ALT、AST 、TBil、ALB）、凝血功能（凝血酶原时间PT ）、HBsAg定量、child-push评分，B超门静脉宽度、门静脉峰值流速均有不同程度的改善。并观察有无不良反应的发生。[结果]24例患者各项指标得到明显改善，疗程中无明显不良反应发生。[结论]拉米夫定治疗失代偿期乙型、丁型重叠感染肝炎肝硬化患者有较好生化学指标改善、HBsAg下降及抗 HBV病毒学应答，部分患者抗 HDV病毒学应答。“,”[Objective]To investigate the clinical efficacy of nucleoside analogues for the treatment of de-compensated liver cirrhosis caused by chronic hepatitis B and D virus ( HBV and HDV ) co-infection .[Methods] A total of 21 patients with liver cirrhosis caused by chronic HBV and HDV co-infection were given nucleoside analogues(lamivudine 100mg ,qd ,adefovir 10mg ,qd or entecavir 0 .5mg ,qd) based on internal medicine treatment .Biochemical indexes ,coagulation function ,Child-Pugh scores ,portal vein width ,portal vein peak flow rate and HBsAg were monitoring during the therapy . Adverse reactions were observed .[Results]All parameters in 21 patients were improved obviously .No adverse reaction occurred during the ther-apy .[Conclusion] Nucleoside drugs for the treatment of patients with the decompensated cirrhosis caused by the co-infection of HBV and HDV can improve biomedical markers and reduce HBsAg ,anti-HBV virology re-sponse and anti-HDV virology response of some patients .